PUBLISHER: The Business Research Company | PRODUCT CODE: 2057561
PUBLISHER: The Business Research Company | PRODUCT CODE: 2057561
The recombinant protein-based biomaterials market for medical devices refers to the segment of the medical materials industry focused on biomaterials produced using recombinant DNA technology. These biomaterials are engineered proteins, such as collagen, elastin, silk, fibrin, and gelatin, manufactured in controlled biological systems to ensure high purity, consistency, and biocompatibility for use in medical devices. The primary purpose of recombinant protein-based biomaterials in medical devices is to enhance safety, performance, and biological integration.
The recombinant protein-based biomaterials market for medical devices market consists of sales by entities (organizations, sole traders and partnerships) of recombinant protein-based biomaterials market for medical devices that are used throughout the lifecycle of medical device development and clinical application from early research and prototyping through regulatory approval, production, and patient care
The global recombinant protein-based biomaterials market for medical devices market was valued at $207.3 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 15.00%.
Increasing Incidence Of Complex And Non-Healing Wounds
During the historic period, the recombinant protein-based biomaterials market for medical devices market was significantly driven by the increasing incidence of complex and non-healing wounds. As the prevalence of chronic health conditions such as diabetes, vascular insufficiencies, and aging-related comorbidities rose globally, healthcare systems experienced a growing burden of wounds that were difficult to heal using conventional treatments, creating demand for advanced wound care solutions that support tissue regeneration and accelerated healing. For instance, in November 2022, according to clinical guidance published by Wounds UK, a UK-based wound care education and best-practice organization supporting clinicians in community and acute care settings, non-healing wounds were identified as a major and persistent challenge within wound management pathways, with evidence indicating that approximately 30% of all wounds are classified as non-healing, despite standard care interventions. The source further noted that non-healing wounds, including diabetic foot ulcers, venous leg ulcers, and pressure injuries, account for a disproportionate share of healthcare resource utilization, contributing to prolonged treatment durations, increased care complexity, and significantly higher overall treatment costs within community healthcare systems. Therefore, the recombinant protein-based biomaterials market for medical devices market was significantly driven by the increasing incidence of complex and non-healing wounds during the historic period.
Introduction Of Recombinant Collagen Platforms To Support Clinical-Grade Biomaterial Solutions
Major companies operating in the recombinant protein-based biomaterials market for medical devices are increasingly focusing on the introduction of clinically enabled recombinant collagen platforms that support advanced therapeutic and implantable applications with improved biological performance, regulatory readiness, and manufacturing consistency. These recombinant collagen materials are engineered using precision biofermentation techniques to closely mimic native human collagen structures, enabling enhanced cell interaction, reduced immunogenicity, and predictable degradation profiles when incorporated into regenerative medical devices and tissue repair products. For instance, in September 2025, Evonik Industries, a Germany-based specialty chemicals and biomaterials manufacturer, launched Vecollan recombinant collagen for use in clinical studies, a platform designed to deliver consistent, high-purity collagen suitable for investigational applications in wound healing, soft tissue reconstruction, and other medical device contexts. Vecollan recombinant collagen is produced through controlled fermentation processes that ensure lot-to-lot reproducibility and comply with clinical-grade quality standards, supporting accelerated translation from research to clinical evaluation.
The global recombinant protein-based biomaterials market for medical devices market is fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 8.84% of the total market in 2024.
Recombinant Protein-Based Biomaterials Market For Medical Devices Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global recombinant protein-based biomaterials market for medical devices market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for recombinant protein-based biomaterials market for medical devices ? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The recombinant protein-based biomaterials market for medical devices market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider recombinant protein-based biomaterials market for medical devices market; and compares it with other markets.
Companies HTL Biotechnology; Jellagen Ltd.; 3D BioFibR Inc.; Creative Biomart Inc.; Collagen Solutions Plc.